DYRK1A

Across TCGA pan-cancer cohorts, DYRK1A mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of DYRK1A’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where DYRK1A mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types DYRK1A is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

CCRCC, LUAD, and LSCC are the cancer types where DYRK1A tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in DYRK1A mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	+0.165	<.001	11	view →
LUAD	All	III,IV	−0.213	<.001	9	view →
LSCC	All	II,III,IV	−0.144	<.001	7	view →
HNSC	All	III,IV	−0.103	.005	6	view →
PDAC	Male	III,IV	−0.397	.001	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

DYRK1A–CCRCC

Open the CCRCC breakdown →